https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=AZURRX_BIOPHARMA_INCAZURRX BIOPHARMA INC - Revizia istoricului2026-04-18T11:57:40ZIstoricul versiunilor pentru această pagină din wikiMediaWiki 1.39.2https://wiki.tradeville.ro/index.php?title=AZURRX_BIOPHARMA_INC&diff=408573&oldid=prevAdmin: Pagină nouă: Pagina dedicata companiei AZURRX BIOPHARMA INC listata cu simbolul US.AZRX ==Descriere companie== First Wave BioPharma, Inc. (www.firstwavebio.com) formerly AzurRx BioPharma, Inc., is a clinical-stage biopharmaceutical company. It is engaged in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. It is focused on advancing a therapeutic development pipeline built around its two technologies: niclosamide, an oral small molecule with anti-vir...2024-09-18T13:41:03Z<p>Pagină nouă: Pagina dedicata companiei AZURRX BIOPHARMA INC listata cu simbolul US.AZRX ==Descriere companie== First Wave BioPharma, Inc. (www.firstwavebio.com) formerly AzurRx BioPharma, Inc., is a clinical-stage biopharmaceutical company. It is engaged in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. It is focused on advancing a therapeutic development pipeline built around its two technologies: niclosamide, an oral small molecule with anti-vir...</p>
<p><b>Pagină nouă</b></p><div>Pagina dedicata companiei AZURRX BIOPHARMA INC listata cu simbolul US.AZRX<br />
<br />
==Descriere companie==<br />
First Wave BioPharma, Inc. (www.firstwavebio.com) formerly AzurRx BioPharma, Inc., is a clinical-stage biopharmaceutical company. It is engaged in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. It is focused on advancing a therapeutic development pipeline built around its two technologies: niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The Company's niclosamide portfolio is led by three clinical programs: FW-COV, for COVID-19 gastrointestinal infections; FW-UP, for ulcerative proctitis (UP) and ulcerative proctosigmoiditis; and FW-ICI-AC, for Grade 1 and Grade 2 immune checkpoint inhibitor-associated colitis and diarrhea in advanced oncology patients. It is also advancing FW-EPI (adrulipase) for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.<br />
<br />
==Grafic actiuni companie==<br />
<iframe key="tradeville" path="graficSimbol/US.AZRX" /><br />
<br />
==Ultimele stiri despre AZURRX BIOPHARMA INC (US.AZRX)==<br />
<dynamicpagelist><br />
category=US.AZRX<br />
count=10<br />
order=descending<br />
addfirstcategorydate=false<br />
</dynamicpagelist><br />
<br />
[[Categorie:US.AZRX]][[Categorie:Stiri despre companii]]</div>Admin